Island Pharmaceuticals Ltd (ILA) Price & Analysis

Q: What was Island Pharmaceuticals Ltd’s price range in the past 12 months?

Island Pharmaceuticals Ltd lowest share price was AU$0.12 and its highest was AU$0.63 in the past 12 months.

Q: What is Island Pharmaceuticals Ltd’s market cap?

Island Pharmaceuticals Ltd’s market cap is AU$109.06M.

Q: When is Island Pharmaceuticals Ltd’s upcoming earnings report date?

Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 181 days.

Q: Is Island Pharmaceuticals Ltd overvalued?

According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Island Pharmaceuticals Ltd pay dividends?

Island Pharmaceuticals Ltd does not currently pay dividends.

Q: What is Island Pharmaceuticals Ltd’s EPS estimate?

Island Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Island Pharmaceuticals Ltd have?

Island Pharmaceuticals Ltd has 294,766,700 shares outstanding.

Q: Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?

Currently, no hedge funds are holding shares in AU:ILA

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

19 Followers

ILA Stock Chart & Stats

AU$0.44

<AU$0.01(1.74%)

At close: Jan 09 4:00 PM EST

AU$0.44

<AU$0.01(1.74%)

Day’s Range― - ―

52-Week RangeAU$0.12 - AU$0.63

Previous CloseN/A

Volume208.69K

Average Volume (3M)781.24K

Market Cap

AU$109.06M

Enterprise ValueAU$86.52M

Total Cash (Recent Filing)AU$7.25M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta-0.55

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding294,766,700

10 Day Avg. Volume388,484

30 Day Avg. Volume781,243

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)3.39

Price to Sales (P/S)204.10

P/FCF Ratio-8.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt and a materially larger equity base provide structural solvency and lower refinancing risk. For a cash-burning biotech, low leverage preserves flexibility to raise equity or partner on R&D without immediate debt servicing pressures, supporting multi‑month runway planning.

Strategic Antiviral FocusA focused antiviral therapeutic strategy targets a durable, high-priority segment of healthcare with recurring demand and partnership interest. Concentrated R&D expertise can improve clinical efficiency, enhance licensing or collaboration prospects, and create clearer go-to-market optionality over months to years.

Cash Burn Modestly ImprovedA measurable reduction in cash burn versus prior year indicates management progress in cost control or program prioritization. Sustained improvement in operating cash outflows lengthens financing runway and reduces the cadence of external capital needs if continued across subsequent quarters.

Bears Say

Sharp 2025 Revenue DeclineA ~70% revenue collapse signals fragile commercial traction or one-off revenue loss, materially weakening the revenue base. Such volatility undermines the predictability of future cashflows, complicates investment prioritization, and increases dependency on external financing or partnerships to sustain operations.

Large And Persistent Net LossesDeep operating and net losses erode shareholder equity and lead to negative returns on invested capital. Over a multi‑quarter horizon sustained losses necessitate recurring fundraising or dilutive financing, which can constrain long-term program execution and shareholder value retention.

Consistent Negative Operating Cash FlowPersistently negative operating and free cash flow creates structural funding risk for R&D and commercialization. Even with no debt, ongoing cash deficits require external capital or partnerships; failure to secure funding could delay programs or force asset sales, impairing long-term competitiveness.

Island Pharmaceuticals Ltd News

Island Pharmaceuticals Defends Handling of FDA Feedback in ASX Query

An announcement from Island Pharmaceuticals Ltd ( ($AU:ILA) ) is now available. Island Pharmaceuticals has responded to an...

10d ago

ILA

Island Pharmaceuticals Outlines Strategy on Urgent Viral Threats in Investor Presentation

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has shared an announcement. Island Pharmaceuticals Limited has released an investor-focused presentation...

15d ago

ILA

Island Pharmaceuticals Plans New Share Placement to Raise Capital

An announcement from Island Pharmaceuticals Ltd ( ($AU:ILA) ) is now available. Island Pharmaceuticals Limited has announced a...

16d ago

ILA

Island Pharmaceuticals Raises A$9m to Accelerate Galidesivir Biodefence Program and US Stockpile Push

The latest update is out from Island Pharmaceuticals Ltd ( ($AU:ILA) ). Island Pharmaceuticals has raised A$9 million...

16d ago

ILA

FDA Backs Island Pharmaceuticals’ Galidesivir Pathway, Opening Route to Accelerated Approval

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has issued an announcement. Island Pharmaceuticals has secured key guidance from the...

16d ago

ILA

Island Pharmaceuticals Requests Trading Halt Ahead of FDA Feedback on Galidesivir

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has provided an announcement. Island Pharmaceuticals Ltd has requested and been granted...

18d ago

ILA

Island Pharmaceuticals Advances Clinical Programs Targeting Urgent Viral Threats

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has issued an update. Island Pharmaceuticals reported that it is progressing two...

24d ago

ILA

Island Pharmaceuticals Secures Key FDA Boost and US Partnerships for Galidesivir Antiviral Program

The latest announcement is out from Island Pharmaceuticals Ltd ( ($AU:ILA) ). Island Pharmaceuticals reported a strategically significant...

24d ago

ILA

Island Pharmaceuticals Issues 8 Million Unquoted Options as Part of Capital Structure

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has provided an update. Island Pharmaceuticals Limited has notified the market of...

2M ago

ILA

Island Pharmaceuticals Awaits Extended FDA Review as Galidesivir Preparations Advance

Island Pharmaceuticals Ltd ( ($AU:ILA) ) just unveiled an update. Island Pharmaceuticals has reported that the US Food...

2M ago

ILA

ILA FAQ

What was Island Pharmaceuticals Ltd’s price range in the past 12 months?

Island Pharmaceuticals Ltd lowest share price was AU$0.12 and its highest was AU$0.63 in the past 12 months.

What is Island Pharmaceuticals Ltd’s market cap?

Island Pharmaceuticals Ltd’s market cap is AU$109.06M.

When is Island Pharmaceuticals Ltd’s upcoming earnings report date?

Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 181 days.

How were Island Pharmaceuticals Ltd’s earnings last quarter?

Currently, no data Available

Is Island Pharmaceuticals Ltd overvalued?

According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Island Pharmaceuticals Ltd pay dividends?

Island Pharmaceuticals Ltd does not currently pay dividends.

What is Island Pharmaceuticals Ltd’s EPS estimate?

Island Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Island Pharmaceuticals Ltd have?

Island Pharmaceuticals Ltd has 294,766,700 shares outstanding.

What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?

Currently, no hedge funds are holding shares in AU:ILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Island Pharmaceuticals Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-90.37%

Trailing 12-Months

Asset Growth

192.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Island Pharmaceuticals Ltd

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.